CALLALY
20.11.2020 12:38:09 CET | Business Wire | Press release
The Tampliner, the period-care innovation created by UK-based B-corp Callaly , has been recognised in TIME’s 100 Best Inventions of 2020 - its annual list of the 100 Best Inventions that are making the world better, smarter and even a bit more fun. Callaly is one of only eight British companies to make this year’s list.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201120005371/en/
Callaly set out to improve the $34bn period care industry with the launch of the Tampliner, a completely new period care product and first design upgrade to the tampon in 90 years. It is a 2-in-1 period product that combines an organic cotton tampon with a soft mini-liner for extra protection against leaks, connected by a ‘virtual applicator’.
The Tampliner, which is designed and manufactured in the UK and was launched in February 2020, was invented by Dr Alex Hooi, a senior British gynaecologist and Fellow of the Royal College of Obstetricians and Gynaecologists and developed by garment technologist Ewa Radziwon, who trained at London College of Fashion.
The British manufactured product is protected by four granted patent families covering 80% of the global market. It is now being exported across Europe in Sweden, the Netherlands and Ireland, and has been trialled with positive results in China.
Callaly, which has raised £13.2m through private investment and government funding, is backed by Innovate UK, having received five tranches totalling £3.9m to support the development and manufacture of the Tampliner. The company employs 20 people in its London HQ.
Callaly’s founder and CEO, Thang Vo-Ta said: “Our whole team is honoured that the Tampliner has been recognised by TIME as a pioneering invention. The period-care industry has been failing people for decades. Little to no R&D in the space means that many people with periods are compromising their health, comfort and convenience, with no choice but to put up with the dissatisfaction they feel. With our 2-in-1 invention we set out to address these problems from every angle and truly make people’s lives better. The Tampliner paves the way for further product innovations to radically improve people’s experiences of periods across the globe.”
Dr Ian Campbell, Executive Chair (Interim) Innovate UK said: "Innovate UK has been proud to support Callaly’s journey over the years, from innovation to manufacturing and now global expansion. This recognition from TIME acknowledges the great potential of R&D-backed British businesses like Callaly to change the world for the better."
Image of the tampliner can be found here .
See the full list here: www.time.com/best-inventions-2020
See the international cover of TIME featuring the 100 Best Inventions of 2020 here: bit.ly/3lJM8ss
ENDS
About Callaly:
British based Callaly is a certified B Corp- a for-profit company that’s committed to using business as a force for good. There are over 3,500 certified B Corps in the world including Danone N. America and Unilever’s Ben & Jerry. Every decision Callaly makes, no matter how small, is taken with an eye on the wider global impact. Callaly donates at least 1% of sales to charities supporting women & children.
Callaly offers a range of high quality period care products managed through its ISO9001 based Quality Management System including award-winning Tampliners, pantyliners, day pads, night pads and tampons- all in a range of different absorbencies. All the products are made with 100% organic cotton and are free from dioxins, perfumes, and pesticides. The Earth-friendly products are all wrapped in sustainable packaging.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201120005371/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 01:00:00 CEST | Press release
Phase 1 study has demonstrated pharmacokinetics (PK) equivalence between SB27 and KeytrudaPhase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sour
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 00:00:00 CEST | Press release
Megaport DDoS Protection removes the trade-off between security, performance, and cost, offering rapid enterprise-grade mitigation. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing s
IFF Reports First Quarter 2026 Results5.5.2026 22:23:00 CEST | Press release
Delivered solid top and bottom line Q1 resultsProgressing disciplined sale process for Food Ingredients businessReaffirms Full Year 2026 Financial Guidance IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks t
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 22:06:00 CEST | Press release
Strong FY 2026 Demonstrates Strategy and Operating Principles Are Delivering SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in
Sentinel Midstream Advances Texas GulfLink Deepwater Port5.5.2026 22:00:00 CEST | Press release
Marks Historic Milestone for U.S. Energy Export Infrastructure under the U.S.-Japan Trade Deal Sentinel Midstream LLC (Sentinel) today announced the commencement of its Texas GulfLink deepwater port (Texas GulfLink or the Project), marking a significant milestone enabled by funding received pursuant to the U.S.—Japan Trade Agreement. The project advances in coordination with the U.S. Department of Commerce and the Government of Japan and reflects the shared commitment to strengthening global energy security and expanding U.S. export infrastructure. Sentinel will lead the development of Texas GulfLink, overseeing construction, commercial operations, and long-term management of the terminal. Funding provided under the U.S.—Japan Trade Agreement, pursuant to Executive Order 14345 signed on September 4, 2025, underscores continued international confidence in U.S. energy infrastructure and supports the expansion of American crude oil exports to global markets. Upon this commencement, Texas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom